Squarepoint Ops LLC acquired a new position in QuidelOrtho Corporation (NASDAQ: QDEL) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 23,774 shares of the company's stock, valued at approximately $685,000. A number of other large investors also recently modified

SAN DIEGO , Dec. 18, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 54 of its Science Bytes podcast, featuring Jonathan Siegrist, PhD, Executive Vice President of Research & Development and Chief Technology Officer at QuidelOrtho. Dr. Siegrist is a recognized leader in molecular diagnostics and biomedical engineering, driving innovation and next-generation diagnostic solutions.

Frontier Capital Management Co. LLC lifted its position in QuidelOrtho Corporation (NASDAQ: QDEL) by 37.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 738,716 shares of the company's stock after buying an additional 201,713 shares during the quarter. Frontier Capital

New York City-based Newtyn Management bought 994,332 shares of QuidelOrtho Corporation in the third quarter, increasing its position by an estimated $30.4 million. At quarter-end, the firm reported holding 2.7 million QDEL shares valued at $79.5 million.

QuidelOrtho Corporation (QDEL) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Ameritas Investment Partners Inc. bought a new stake in QuidelOrtho Corporation (NASDAQ: QDEL) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,923 shares of the company's stock, valued at approximately $200,000. Other institutional investors have also bought

SAN DIEGO , Nov. 24, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global leader of in vitro diagnostics, announced today that members of its management team will participate in two upcoming investor conferences: Evercore ISI 8th Annual Healthcare Conference, Tuesday, December 2, 2025 Members of QuidelOrtho's management team are scheduled to participate in a fireside chat at 10:00 a.m. ET / 7:00 a.m.

SAN DIEGO , Nov. 20, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 53 of its Science Bytes podcast, featuring Qian Ding, MD, PhD, Senior Medical Affairs Manager, QuidelOrtho, an expert in clinical and laboratory medicine with deep experience in healthcare information systems and data analytics. In the episode titled "Don't Wait for the Wake-Up Call," Dr. Ding explains why early detection of diabetes is a clinical and economic priority.

Bank of New York Mellon Corp increased its stake in shares of QuidelOrtho Corporation (NASDAQ: QDEL) by 3.0% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 428,432 shares of the company's stock after acquiring an additional 12,668 shares

QDEL tops Q3 estimates as Labs and Immunohematology units drive growth, while margins strengthen despite respiratory revenue declines.